Kala Pharmaceuticals, Inc. (Kala) is a clinical-stage pharmaceutical company focused on innovative nanoparticle-based treatments for ocular diseases affecting both front and back of the eye. Kala leverages its proprietary mucus-penetrating particle (MPP) technology to develop topical ophthalmic formulations with enhanced delivery into ocular tissue by facilitating penetration through the tear film mucus. Kala’s lead program, a shelf-stable MPP nanosuspension of an ophthalmic corticosteroid, is in clinical trials for the treatment of post-surgical ocular inflammation, dry eye disease, and meibomian gland disease.
Kala is also advancing its novel, small molecule receptor tyrosine kinase inhibitor (RTKi) program as a potential topical treatment of wet age-related macular degeneration (AMD). Beyond ophthalmology, Kala’s MPP technology has potential applications in women’s reproductive health, respiratory and gastrointestinal diseases, and other indications.
|HQ||Watertown, MA, US||Map|
Net income (FY, 2016)
EBIT (FY, 2016)
Market capitalization (15-Jan-2021)
Closing stock price (15-Jan-2021)
When was Kala Pharmaceuticals founded?
Kala Pharmaceuticals was founded in 2009.
Who are Kala Pharmaceuticals key executives?
Kala Pharmaceuticals's key executives are Mark Iwicki, Kim Brazzell and Howard B. Rosen.
How many employees does Kala Pharmaceuticals have?
Kala Pharmaceuticals has 37 employees.
Who are Kala Pharmaceuticals competitors?
Competitors of Kala Pharmaceuticals include GT Biopharma, PTC Therapeutics and Pulmatrix.
Where is Kala Pharmaceuticals headquarters?
Kala Pharmaceuticals headquarters is located at 490 Arsenal Way #120Watertown, Watertown.
Where are Kala Pharmaceuticals offices?
Kala Pharmaceuticals has offices in Watertown and Waltham.
How many offices does Kala Pharmaceuticals have?
Kala Pharmaceuticals has 2 offices.
Receive alerts for 300+ data fields across thousands of companies